



Press release

Stockholm, February 04, 2022

## Peter Hentschel appointed as Chairman at CytaCoat

**CytaCoat AB, developers of the unique CytaCoat anti-microbial coating technology, have appointed Peter Hentschel as Chairman.**

Peter brings a wealth of knowledge from his highly relevant and extensive experience in the medical device field, both operationally and while serving as a Board member of several medtech businesses, including both large multi-national companies and smaller, highly innovative technology-based businesses.

Previously he has served as Senior Vice President of Mölnlycke Health Care, CEO of Etac AB and had senior positions within SCA Hygiene Products.

He has also served as a Board member at a large number of companies, including Bactiguard AB, and has been Chairman of the Board at RLS Global AB, Reapplix A/S, Diasend AB and Lumina Adhesives AB.

During his time as Chairman at Reapplix, Peter worked with CytaCoat CEO, Graeme Brookes, who was formerly the CEO at Reapplix A/S. Peter and Graeme worked together at Reapplix for six years and successfully led the Company through product development, regulatory, clinical trial (published in The Lancet) and US reimbursement phases, successfully paving the way for Reapplix to implement its strategy to undertake direct commercialization in the USA with US based leadership.

With the appointment of Peter as CytaCoat Chairman, Per Wirsén will now take on the responsibility of Deputy Chairman and will continue as a Board member. Per will also continue to be fully involved operationally in the new role of Chief Operating Officer.

Peter Hentschel, now appointed as Chairman of CytaCoat AB, said:

*"I am delighted to join the CytaCoat Board at this exciting time where the technology begins its scale up to pilot plant manufacturing and the next phase of clinical investigation work is initiated. There has been significant progress to date and we are all looking forward to continuing to drive the company forward".*

### FURTHER INFORMATION:

GRAEME BROOKES, CEO

+44 7572425331

[graeme.brookes@cytacoat.se](mailto:graeme.brookes@cytacoat.se)

### ABOUT CYTACOAT

CytaCoat AB is a privately held company based at the Karolinska Institute Science Park with a strong Swedish investor base, including Segulah Medical Acceleration. The company has developed the CytaCoat anti-microbial coating for medical devices, with the objective of preventing healthcare-associated infections, one of the biggest problems in healthcare today. An effective anti-microbial coating can destroy or inhibit the growth of microorganisms, including bacteria, fungi and viruses.

CytaCoat's anti-microbial coating contains only non-toxic, biocompatible organic components and has been successfully applied to many materials used in the medical device industry. The company is now moving forward from lab scale coating development and technology optimization to build a pilot coating plant, which will support the manufacturing of coated devices for clinical investigations. The company aims to license the technology to leading, established medical device players for multiple application-specific devices.

See [www.cytacoat.com](http://www.cytacoat.com)